These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 14508076)

  • 1. Novel anticancer agents in clinical development.
    Adjei AA; Rowinsky EK
    Cancer Biol Ther; 2003; 2(4 Suppl 1):S5-15. PubMed ID: 14508076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal transduction pathway targets for anticancer drug discovery.
    Adjei AA
    Curr Pharm Des; 2000 Mar; 6(4):361-78. PubMed ID: 10788587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies in gynecologic cancers.
    Chon HS; Hu W; Kavanagh JJ
    Curr Cancer Drug Targets; 2006 Jun; 6(4):333-63. PubMed ID: 16848724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of target of rapamycin inhibitors.
    Easton JB; Houghton PJ
    Expert Opin Ther Targets; 2004 Dec; 8(6):551-64. PubMed ID: 15584862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Molecular Targets of Anticancer Therapy - Current Status and Perspectives.
    Zajac M; Muszalska I; Jelinska A
    Curr Med Chem; 2016; 23(37):4176-4220. PubMed ID: 27528054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel pharmacological agents in clinical development for solid tumours.
    Dy GK; Haluska P; Adjei AA
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2059-88. PubMed ID: 11772306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
    Fabbro D; Ruetz S; Buchdunger E; Cowan-Jacob SW; Fendrich G; Liebetanz J; Mestan J; O'Reilly T; Traxler P; Chaudhuri B; Fretz H; Zimmermann J; Meyer T; Caravatti G; Furet P; Manley PW
    Pharmacol Ther; 2002; 93(2-3):79-98. PubMed ID: 12191602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular approach to breast cancer treatment.
    Yarden Y; Baselga J; Miles D
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):6-13. PubMed ID: 15490369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling galectin-1 as a novel therapeutic target for cancer.
    Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
    Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.
    Rao RD; Buckner JC; Sarkaria JN
    Curr Cancer Drug Targets; 2004 Dec; 4(8):621-35. PubMed ID: 15578919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Key cancer cell signal transduction pathways as therapeutic targets.
    Bianco R; Melisi D; Ciardiello F; Tortora G
    Eur J Cancer; 2006 Feb; 42(3):290-4. PubMed ID: 16376541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy.
    Tortora G; Ciardiello F
    Ann N Y Acad Sci; 2003 Dec; 1002():236-43. PubMed ID: 14751838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
    Perego P; Cossa G; Zuco V; Zunino F
    Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raf kinase as a target for anticancer therapeutics.
    Sridhar SS; Hedley D; Siu LL
    Mol Cancer Ther; 2005 Apr; 4(4):677-85. PubMed ID: 15827342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment.
    Spänkuch B; Strebhardt K
    Curr Pharm Des; 2008; 14(11):1098-112. PubMed ID: 18473857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
    Asati V; Mahapatra DK; Bharti SK
    Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.